Back to Search
Start Over
Effect of Early Normotension with Olmesartan on Rho-kinase Activity in Hypertensive Patients
- Source :
- Current Vascular Pharmacology. 18:87-91
- Publication Year :
- 2019
- Publisher :
- Bentham Science Publishers Ltd., 2019.
-
Abstract
- Background: Angiotensin II is a potent activator of the Rho-kinase (ROCK) pathway, through which it exerts some of its adverse vasoconstrictor effects. Clinical evidence on the effects of blocking the angiotensin II receptor 1 on ROCK activity in hypertensive patients is scarce. Objective: To demonstrate that ROCK activity in peripheral blood mononuclear cells (PMBCs) in patients with essential hypertension is reduced earlier than previously observed, along with blood pressure (BP) lowering on treatment with olmesartan. Methods: Prospective pilot open study; 17 hypertensive patients were treated with progressive olmesartan doses starting with 20 mg qd. BP was measured at 3, 6 and 9 weeks after treatment initiation. If treatment failed to normalize BP after 3 weeks, olmesartan dose was increased to 40 mg qd, and if still hypertensive after 6 weeks, 12.5 mg of hydrochlorothiazide qd was added. ROCK activity was measured at baseline and 9 weeks after treatment as myosin phosphatase target subunit 1 phosphorylation (MYPT1-p/T ratio) in PBMC. Results: Mean baseline BP was 162 ± 4.9/101 ± 2.4 mmHg. After 9 weeks of treatment, both systolic and diastolic BP were reduced by 41 and 22 mmHg, respectively (p Conclusion: Normotension achieved after 9 weeks in 82% of the patients treated with olmesartan was associated with a significant reduction of ROCK activity in PBMC.
- Subjects :
- Adult
Male
0301 basic medicine
medicine.medical_specialty
Angiotensin receptor
Time Factors
Diastole
Down-Regulation
Tetrazoles
Blood Pressure
Pilot Projects
030204 cardiovascular system & hematology
Essential hypertension
Peripheral blood mononuclear cell
Myosin-Light-Chain Phosphatase
03 medical and health sciences
0302 clinical medicine
Hydrochlorothiazide
Internal medicine
medicine
Humans
Prospective Studies
Phosphorylation
Antihypertensive Agents
Pharmacology
rho-Associated Kinases
business.industry
Imidazoles
Middle Aged
medicine.disease
Angiotensin II
Treatment Outcome
030104 developmental biology
Blood pressure
Endocrinology
Leukocytes, Mononuclear
Female
Essential Hypertension
Cardiology and Cardiovascular Medicine
Olmesartan
business
Angiotensin II Type 1 Receptor Blockers
medicine.drug
Subjects
Details
- ISSN :
- 15701611
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- Current Vascular Pharmacology
- Accession number :
- edsair.doi.dedup.....8ac7ee76ed6c893125bff1c6ee6da193